经导管三尖瓣介入治疗:现状、挑战与未来方向
三尖瓣反流常见于左侧瓣膜或心肌病患者,常为晚期慢性心衰标志且预后差;孤立三尖瓣手术罕见且死亡率最高。近年多种经导管三尖瓣修复与置换技术涌现,本综述概述其现状、挑战与未来方向。
要点
- 三尖瓣反流是晚期慢性心衰标志,孤立三尖瓣手术死亡率居所有瓣膜手术之首。
- 经导管三尖瓣修复与置换为重度三尖瓣反流提供微创治疗新选择。
- 综述强调该领域挑战与未来方向,临床需求远未满足。
核心结论
- 经导管三尖瓣修复与置换为重度三尖瓣反流患者开辟了全新治疗途径。
研究设计与样本
- 本文为综述,旨在更新经导管三尖瓣治疗的概况与临床视角。
主要发现
- 三尖瓣反流常见于左侧瓣膜或心肌病患者,常为晚期慢性心衰标志且预后差。
- 孤立三尖瓣手术不常进行,且在所有瓣膜手术中死亡率最高。
- 近年多种经皮三尖瓣修复及置换技术被开发用于治疗重度三尖瓣反流。
临床怎么用
- 对重度三尖瓣反流且外科高危患者,可关注经导管修复或置换的适应证与时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tricuspid regurgitation is a common finding in patients with left-sided valvular or myocardial disease, often being a marker for late-stage chronic heart failure with a grim prognosis. However, isolated tricuspid valve surgery remains infrequent and is associated with the highest mortality among all valve procedures. Hence, a largely unmet clinical need exists for less invasive therapeutic options in these patients. In recent times, multiple percutaneous therapies have been developed for treating severe tricuspid regurgitation, including tricuspid valve repair and, more recently replacement, opening an entirely new venue for managing tricuspid regurgitation. The aim of this review is to provide an updated overview and a clinical perspective on novel transcatheter tricuspid valve therapies, highlighting potential challenges and future directions.
引用
- Asmarats L, Puri R, Latib A, et al. Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions. J Am Coll Cardiol. 2018. PMID: 29929618. doi:10.1016/j.jacc.2018.04.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。